(MedPage Today) — Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, and an increased risk of…
Source link : https://www.medpagetoday.com/recent-developments/dlbcl-cll/117684
Author :
Publish date : 2025-09-29 12:45:00
Copyright for syndicated content belongs to the linked Source.
